Details of Drug-Metabolizing Enzyme (DME)

General Information of Drug-Metabolizing Enzyme (DME) (ID: DEQ2BAJ)

DME Name	Acetylcholinesterase (ACHE)
Synonyms	Acetylhydrolase; Primary cholinesterase; ACHE; AChE; Acetylcholinesterase (Yt blood group); ACEE; ARN-YT; Acetylcholinesterase (Cartwright blood group); True cholinesterase
Gene Name	ACHE
UniProt ID	ACES_HUMAN
INTEDE ID	DME0058
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
Gene ID	43
EC Number	EC: 3.1.1.7 Hydrolases Ester bond hydrolase Carboxylic ester hydrolase EC: 3.1.1.7
Lineage	Species: Homo sapiens Kingdom: Metazoa Phylum: Chordata Class: Mammalia Order: Primates Family: Hominidae Genus: Homo Species: Homo sapiens
Sequence	MRPPQCLLHTPSLASPLLLLLLWLLGGGVGAEGREDAELLVTVRGGRLRGIRLKTPGGPV SAFLGIPFAEPPMGPRRFLPPEPKQPWSGVVDATTFQSVCYQYVDTLYPGFEGTEMWNPN RELSEDCLYLNVWTPYPRPTSPTPVLVWIYGGGFYSGASSLDVYDGRFLVQAERTVLVSM NYRVGAFGFLALPGSREAPGNVGLLDQRLALQWVQENVAAFGGDPTSVTLFGESAGAASV GMHLLSPPSRGLFHRAVLQSGAPNGPWATVGMGEARRRATQLAHLVGCPPGGTGGNDTEL VACLRTRPAQVLVNHEWHVLPQESVFRFSFVPVVDGDFLSDTPEALINAGDFHGLQVLVG VVKDEGSYFLVYGAPGFSKDNESLISRAEFLAGVRVGVPQVSDLAAEAVVLHYTDWLHPE DPARLREALSDVVGDHNVVCPVAQLAGRLAAQGARVYAYVFEHRASTLSWPLWMGVPHGY EIEFIFGIPLDPSRNYTAEEKIFAQRLMRYWANFARTGDPNEPRDPKAPQWPPYTAGAQQ YVSLDLRPLEVRRGLRAQACAFWNRFLPKLLSATDTLDEAERQWKAEFHRWSSYMVHWKN QFDHYSKQDRCSDL
Function	This enzyme hydrolyzes of the acetylcholine released into the synaptic cleft to terminate signal transduction at the neuromuscular junction.
KEGG Pathway	( ) ( )
Reactome Pathway	Synthesis of PC (R-HSA-1483191 ) Synthesis, secretion, and deacylation of Ghrelin (R-HSA-422085 ) Neurotransmitter clearance (R-HSA-112311 )

Molecular Interaction Atlas (MIA) of This DME

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This DME

2 Approved Drug(s) Metabolized by This DME

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetylcholine	DMDF79Z	Cataract	9B10	Approved	[120]
Heroin diacetylmorphine	DMDBWHY	Neurological disorder	6B60	Approved	[121]
------------------------------------------------------------------------------------

Molecular Expression Atlas (MEA) of This DME

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This DME

Disease Name	ICD 11	Studied Tissue	p-value	Fold-Change	Z-score
Acute myelocytic leukaemia	2B33.1	Bone marrow	1.79E-04	-2.52E-01	-5.08E-01
Alopecia	ED70	Skin from scalp	2.58E-01	1.09E-01	3.80E-01
Alzheimer's disease	8A20	Entorhinal cortex	2.73E-04	-1.64E-01	-5.36E-01
Ankylosing spondylitis	FA92.0	Pheripheral blood	2.39E-01	5.22E-02	3.95E-01
Aortic stenosis	BB70	Calcified aortic valve	3.13E-01	-1.42E-01	-3.62E-01
Apnea	7A40	Hyperplastic tonsil	7.42E-01	-7.59E-03	-3.63E-02
Arthropathy	FA00-FA5Z	Peripheral blood	2.76E-01	-6.10E-03	-4.18E-02
Asthma	CA23	Nasal and bronchial airway	9.50E-02	-4.32E-02	-1.63E-01
Atopic dermatitis	EA80	Skin	2.57E-04	-1.67E-01	-1.00E+00
Autism	6A02	Whole blood	1.56E-01	-1.37E-01	-4.63E-01
Autoimmune uveitis	9A96	Peripheral monocyte	8.43E-06	-2.38E-01	-1.46E+00
Autosomal dominant monocytopenia	4B04	Whole blood	1.40E-01	1.31E-02	8.00E-02
Bacterial infection of gingival	1C1H	Gingival tissue	8.23E-02	1.58E-02	7.03E-02
Batten disease	5C56.1	Whole blood	9.63E-01	1.19E-02	7.53E-02
Behcet's disease	4A62	Peripheral blood	9.41E-01	1.81E-03	1.03E-02
Bipolar disorder	6A60-6A6Z	Prefrontal cortex	8.21E-01	-6.02E-03	-3.77E-02
Bladder cancer	2C94	Bladder tissue	4.17E-02	2.71E-01	1.06E+00
Breast cancer	2C60-2C6Z	Breast tissue	1.03E-03	5.43E-02	2.40E-01
Cardioembolic stroke	8B11.20	Whole blood	9.52E-01	-3.26E-03	-9.32E-03
Cervical cancer	2C77	Cervical tissue	4.09E-01	-4.01E-02	-2.15E-01
Childhood onset rheumatic disease	FA20.Z	Peripheral blood	5.05E-01	-9.48E-04	-2.80E-03
Chronic hepatitis C	1E51.1	Whole blood	2.66E-01	1.02E-01	4.13E-01
Chronic obstructive pulmonary disease	CA22	Lung tissue	4.08E-01	1.14E-02	5.47E-02
Chronic obstructive pulmonary disease	CA22	Small airway epithelium	2.63E-01	2.88E-02	1.33E-01
Chronic rhinosinusitis	CA0A	Sinus mucosa tissue	4.09E-01	6.05E-02	4.84E-01
Colon cancer	2B90	Colon tissue	4.75E-17	-2.94E-01	-9.24E-01
Coronary artery disease	BA80-BA8Z	Peripheral blood	4.04E-01	-1.04E-01	-9.05E-01
Diffuse large B-cell lymphoma	2A81	Tonsil tissue	9.57E-01	7.48E-02	2.86E-01
Endometriosis	GA10	Endometrium tissue	6.07E-01	-1.10E-02	-4.78E-02
Familial hypercholesterolemia	5C80.00	Peripheral blood	3.07E-01	-5.60E-02	-3.31E-01
Familial hypercholesterolemia	5C80.00	Whole blood	1.64E-01	-1.90E-01	-7.04E-01
Gastric cancer	2B72	Gastric tissue	9.95E-01	-2.65E-01	-9.20E-01
Glioblastopma	2A00.00	Nervous tissue	1.19E-58	-7.00E-01	-1.14E+00
Glioma	2A00.0Y-2A00.0Z	Brain stem tissue	2.32E-01	-6.61E-01	-1.60E+00
Glioma	2A00.0Y-2A00.0Z	White matter tissue	1.41E-01	8.24E-02	3.37E-01
Head and neck cancer	2D42	Head and neck tissue	2.01E-02	8.65E-03	3.01E-02
HIV-associated neurocognitive impairment	8A2Y-8A2Z	White matter tissue	7.16E-02	-4.47E-01	-1.07E+00
Huntington's disease	8A01.10	Whole blood	5.38E-01	-8.72E-02	-4.45E-01
Idiopathic pulmonary fibrosis	CB03.4	Lung tissue	1.44E-01	2.67E-01	1.07E+00
Immunodeficiency	4A00-4A20	Peripheral blood	1.66E-01	9.82E-02	8.90E-01
Influenza	1E30	Whole blood	1.58E-01	2.07E-01	1.11E+00
Interstitial cystitis	GC00.3	Bladder tissue	3.12E-01	1.24E-01	6.01E-01
Intracranial aneurysm	8B01.0	Intracranial artery	7.95E-01	-8.21E-02	-2.35E-01
Irritable bowel syndrome	DD91.0	Rectal colon tissue	1.15E-01	-8.14E-02	-3.51E-01
Ischemic stroke	8B11	Peripheral blood	5.51E-01	2.55E-02	1.52E-01
Juvenile idiopathic arthritis	FA24	Peripheral blood	3.27E-07	2.14E-01	7.15E-01
Lateral sclerosis	8B60.4	Skin	4.89E-01	8.25E-02	5.61E-01
Lateral sclerosis	8B60.4	Cervical spinal cord	3.37E-02	4.41E-01	1.32E+00
Liver cancer	2C12.0	Liver tissue	1.54E-01	-1.47E-01	-6.31E-01
Liver failure	DB99.7-DB99.8	Liver tissue	6.79E-01	1.99E-01	6.85E-01
Lung cancer	2C25	Lung tissue	3.78E-04	2.40E-02	1.04E-01
Lupus erythematosus	4A40	Whole blood	6.83E-04	-1.71E-01	-2.36E-01
Major depressive disorder	6A70-6A7Z	Hippocampus	4.42E-01	2.98E-02	1.91E-01
Major depressive disorder	6A70-6A7Z	Whole blood	7.08E-01	-2.92E-02	-9.80E-02
Melanoma	2C30	Skin	9.07E-01	-2.82E-02	-6.90E-02
Multiple myeloma	2A83.1	Peripheral blood	3.28E-01	-3.79E-02	-3.42E-01
Multiple myeloma	2A83.1	Bone marrow	1.48E-03	2.55E-01	1.58E+00
Multiple sclerosis	8A40	Plasmacytoid dendritic cells	5.95E-01	-8.52E-03	-4.77E-02
Myelodysplastic syndrome	2A36-2A3Z	Bone marrow	8.25E-01	-6.24E-04	-2.70E-03
Myelofibrosis	2A20.2	Whole blood	1.52E-03	1.40E-01	9.53E-01
Myocardial infarction	BA41-BA50	Peripheral blood	7.11E-03	3.90E-01	8.69E-01
Myopathy	8C70.6	Muscle tissue	8.27E-01	-1.36E-01	-4.00E-01
Neonatal sepsis	KA60	Whole blood	8.66E-01	-1.67E-02	-6.52E-02
Neuroectodermal tumour	2A00.11	Brain stem tissue	3.28E-05	-9.27E-01	-2.33E+00
Non-alcoholic fatty liver disease	DB92	Liver tissue	6.20E-01	8.68E-02	5.60E-01
Obesity related type 2 diabetes	5A11	Omental adipose tissue	9.66E-01	-1.36E-02	-7.84E-02
Olive pollen allergy	CA08.00	Peripheral blood	4.07E-01	1.01E-01	8.78E-01
Oral cancer	2B6E	Oral tissue	1.37E-03	-3.64E-01	-5.37E-01
Osteoarthritis	FA00-FA0Z	Synovial tissue	5.82E-01	6.41E-03	1.78E-02
Osteoporosis	FB83.1	Bone marrow	1.43E-02	3.53E-01	1.48E+00
Ovarian cancer	2C73	Ovarian tissue	5.37E-02	-3.12E-01	-1.15E+00
Pancreatic cancer	2C10	Pancreas	2.65E-02	-2.74E-01	-7.08E-01
Parkinson's disease	8A00.0	Substantia nigra tissue	6.39E-02	-1.07E+00	-1.15E+00
Pediatric respiratory syncytial virus infection	CA40.11	Peripheral blood	9.29E-01	-4.62E-02	-3.60E-01
Pituitary cancer	2D12	Pituitary tissue	1.03E-05	7.01E-01	2.90E+00
Pituitary gonadotrope tumour	2D12	Pituitary tissue	1.28E-04	8.17E-01	3.01E+00
Polycystic ovary syndrome	5A80.1	Vastus lateralis muscle	4.08E-01	2.32E-02	8.57E-02
Polycythemia vera	2A20.4	Whole blood	8.37E-04	1.34E-01	7.84E-01
Pompe disease	5C51.3	Biceps muscle	2.53E-02	-3.29E-01	-8.14E-01
Preterm birth	KA21.4Z	Myometrium	7.46E-01	0.00E+00	0.00E+00
Prostate cancer	2C82	Prostate	6.97E-04	-5.07E-01	-1.11E+00
Psoriasis	EA90	Skin	1.76E-04	-2.74E-01	-6.39E-01
Rectal cancer	2B92	Rectal colon tissue	2.57E-03	-5.09E-01	-2.25E+00
Renal cancer	2C90-2C91	Kidney	2.15E-01	5.90E-02	2.97E-01
Retinoblastoma	2D02.2	Uvea	2.12E-05	-1.40E+00	-2.11E+00
Rheumatoid arthritis	FA20	Synovial tissue	7.58E-01	1.36E-01	3.85E-01
Rhinovirus infection	CA42.1	Nasal epithelium tissue	3.05E-01	-6.54E-04	-3.54E-03
Schizophrenia	6A20	Prefrontal cortex	8.17E-02	-9.22E-02	-2.15E-01
Schizophrenia	6A20	Superior temporal cortex	3.02E-01	-1.25E-01	-4.97E-01
Scleroderma	4A42.Z	Whole blood	1.46E-01	9.92E-02	4.43E-01
Seizure	8A60-8A6Z	Whole blood	3.98E-01	-1.61E-01	-7.63E-01
Sensitive skin	EK0Z	Skin	2.50E-01	-5.65E-02	-5.39E-01
Sepsis with septic shock	1G41	Whole blood	1.99E-01	-2.09E-02	-8.95E-02
Shwachman-Diamond syndrome	3A70.0	Bone marrow	1.31E-01	2.48E-01	1.12E+00
Sickle cell disease	3A51.0-3A51.3	Peripheral blood	4.09E-01	8.34E-03	4.16E-02
Simpson golabi behmel syndrome	LD2C	Adipose tissue	7.33E-01	2.12E-01	4.22E-01
Sjogren's syndrome	4A43.2	Salivary gland tissue	4.03E-03	-2.42E-01	-2.66E+00
Skin cancer	2C30-2C3Z	Skin	5.06E-14	-2.51E-01	-5.18E-01
Thrombocythemia	3B63	Whole blood	7.39E-01	2.16E-02	1.22E-01
Thrombocytopenia	3B64	Whole blood	7.31E-01	1.83E-01	7.23E-01
Thyroid cancer	2D10	Thyroid	8.01E-01	-3.67E-02	-1.45E-01
Tibial muscular dystrophy	8C75	Muscle tissue	9.25E-01	1.17E-01	1.29E-01
Tuberous sclerosis complex	LD2D.2	Perituberal tissue	4.96E-02	-2.69E-01	-1.30E+00
Type 2 diabetes	5A11	Liver tissue	1.12E-01	-2.12E-01	-8.10E-01
Ureter cancer	2C92	Urothelium	3.77E-01	-4.10E-03	-2.43E-02
Uterine cancer	2C78	Endometrium tissue	2.84E-07	-1.54E-01	-5.59E-01
Vitiligo	ED63.0	Skin	2.45E-01	-9.48E-02	-4.57E-01
------------------------------------------------------------------------------------


⏷ Show the Full List of DME Expression Under 107 Diseases

The Drug Therapeutic Target (DTT) Role of This DME

DME DTT Name

Acetylcholinesterase (AChE) DTT Info

DME DTT Type

Successful

15 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ambenonium	DMOP0BL	Myasthenia gravis	8C6Y	Approved	[1]
Demecarium bromide	DMAYEU1	Open-angle glaucoma	9C61	Approved	[2], [3]
Donepezil	DMIYG7Z	Alzheimer disease	8A20	Approved	[4]
Echothiophate Iodide	DMSNVGB	Chronic glaucoma	9C61.0Z	Approved	[5]
Edrophonium	DMCRQHB	Myasthenia gravis	8C6Y	Approved	[6], [7], [8]
Galantamine	DMEO794	Alzheimer disease	8A20	Approved	[9], [10], [11]
Huperzine A	DMMAWLU	Alzheimer disease	8A20	Approved	[12]
Isoflurophate	DMBSK7X	Glaucoma/ocular hypertension	9C61	Approved	[13]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[14]
Neostigmine	DM6T2J3	Myasthenia gravis	8C6Y	Approved	[6], [7]
Pralidoxime chloride	DMGQ0ZI	Poisoning due to pesticides and chemicals	NE6Z	Approved	[5]
Pyridostigmine	DM8HO1L	Myasthenia gravis	8C6Y	Approved	[7]
Rivastigmine	DMG629M	Alzheimer disease	8A20	Approved	[4]
Tacrine	DM51FY6	Alzheimer disease	8A20	Approved	[15]
YM443	DMNZCI1	Functional dyspepsia	DD90.3	Approved	[16]
------------------------------------------------------------------------------------


⏷ Show the Full List of 15 Approved Drug(s)

16 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(-)-Phenserine	DMNCY1I	Alzheimer disease	8A20	Phase 3	[17]
Amocarzine	DMB9587	Helminth infection	1F90.0	Phase 3	[18]
Eptastigmine	DMTV7ZM	Cognitive impairment	6D71	Phase 3	[19], [20]
INM-176	DMLG96Z	Alzheimer disease	8A20	Phase 3	[21]
Suronacrine maleate	DMH2FN1	Cognitive impairment	6D71	Phase 3	[22]
Ladostigil	DMJSY3Q	Alzheimer disease	8A20	Phase 2	[23]
Methanesulfonyl fluoride	DMS7FRI	Alzheimer disease	8A20	Phase 2	[24]
R-phenserine	DM4L5VJ	Alzheimer disease	8A20	Phase 2	[25]
T-82	DM4JFMZ	Cognitive impairment	6D71	Phase 2	[26], [16]
CPC-212	DM3J1T9	Alzheimer disease	8A20	Phase 1	[27], [28]
CPC-250	DMDQG4Y	Alzheimer disease	8A20	Phase 1	[27], [28]
Desoxypeganine	DMTR7EH	Alcohol dependence	6C40.2	Phase 1	[29]
GTP-004	DM20HS7	Myasthenia gravis	8C6Y	Phase 1	[27]
KW-5092	DMALK7F	Pain	MG30-MG3Z	Phase 1	[30]
PRX-105	DMWT8RI	Poison intoxication	NE6Z	Phase 1	[31]
ZT-1	DMO2WYX	Parkinson disease	8A00.0	Phase 1	[32], [16]
------------------------------------------------------------------------------------


⏷ Show the Full List of 16 Clinical Trial Drug(s)

54 Patented Agent(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2-PAM derivative 1	DMI4KBC	N. A.	N. A.	Patented	[33]
4-PAM derivative 1	DMN37BI	N. A.	N. A.	Patented	[33]
Amidine oxime derivative 1	DM8STUQ	N. A.	N. A.	Patented	[33]
Decyle nelycorine dibromo salt derivative 1	DMXKUMJ	N. A.	N. A.	Patented	[34]
Di-substituted piperidine derivative 2	DM23XQL	N. A.	N. A.	Patented	[34]
Egonol compound 1	DMQF1UM	N. A.	N. A.	Patented	[33]
Fluorinated donepezil derivative 1	DMQOGHN	N. A.	N. A.	Patented	[33]
Fluorinated donepezil derivative 2	DMV1SCA	N. A.	N. A.	Patented	[33]
Galantamine analog 1	DM5BVCS	N. A.	N. A.	Patented	[33]
Indoline derivative 1	DMJ41UI	N. A.	N. A.	Patented	[34]
Isochroman-4-ketone derivative 1	DMDBK6O	N. A.	N. A.	Patented	[34]
Lycorine dimer salt derivative 1	DMGKQXP	N. A.	N. A.	Patented	[33]
PMID27967267-Compound-12	DMBNHI7	N. A.	N. A.	Patented	[33]
PMID27967267-Compound-13	DMY5UB8	N. A.	N. A.	Patented	[33]
PMID27967267-Compound-14	DMGI5Z8	N. A.	N. A.	Patented	[33]
PMID27967267-Compound-15	DMEW46T	N. A.	N. A.	Patented	[33]
PMID27967267-Compound-27	DMO0QME	N. A.	N. A.	Patented	[33]
PMID27967267-Compound-28	DMVM31E	N. A.	N. A.	Patented	[33]
PMID27967267-Compound-3	DM7JIF0	N. A.	N. A.	Patented	[33]
PMID27967267-Compound-36	DM7CWZ4	N. A.	N. A.	Patented	[33]
PMID27967267-Compound-39	DMQOAJP	N. A.	N. A.	Patented	[33]
PMID27967267-Compound-42	DM68KPS	N. A.	N. A.	Patented	[33]
PMID27967267-Compound-43	DM12X0P	N. A.	N. A.	Patented	[33]
PMID27967267-Compound-47	DMEXATH	N. A.	N. A.	Patented	[33]
PMID27967267-Compound-48	DM81A50	N. A.	N. A.	Patented	[33]
PMID27967267-Compound-49	DMQTRFX	N. A.	N. A.	Patented	[33]
PMID27967267-Compound-51	DMNH891	N. A.	N. A.	Patented	[33]
PMID27967267-Compound-52	DMRH7ZY	N. A.	N. A.	Patented	[33]
PMID27967267-Compound-7	DMAN71J	N. A.	N. A.	Patented	[33]
PMID27967267-Compound-neostenine	DM7TLDW	N. A.	N. A.	Patented	[33]
PMID27967267-Compound-neotuberostemonine	DM3CPJQ	N. A.	N. A.	Patented	[33]
PMID27967267-Compound-stenine	DM2K54D	N. A.	N. A.	Patented	[33]
PMID29757691-Compound-10	DMZBHR9	N. A.	N. A.	Patented	[34]
PMID29757691-Compound-2a	DMEUC04	N. A.	N. A.	Patented	[34]
PMID29757691-Compound-2a-i	DMBRQP1	N. A.	N. A.	Patented	[34]
PMID29757691-Compound-4	DMFD9UZ	N. A.	N. A.	Patented	[34]
PMID29757691-Compound-7	DM7TPBF	N. A.	N. A.	Patented	[34]
PMID29757691-Compound-8a	DM5IFBV	N. A.	N. A.	Patented	[34]
PMID29757691-Compound-8b	DMEOZKF	N. A.	N. A.	Patented	[34]
PMID29757691-Compound-8c	DMHL7SW	N. A.	N. A.	Patented	[34]
PMID29757691-Compound-8d	DM6PDEH	N. A.	N. A.	Patented	[34]
Quinazoline alkaloid derivative 1	DMH86F2	N. A.	N. A.	Patented	[34]
Tacrine heterodimer derivative 1	DMFOKRW	N. A.	N. A.	Patented	[34]
Tacrine-caffeic acid hybrid derivative 1	DMJ04RQ	N. A.	N. A.	Patented	[33]
Tacrine-caffeic acid hybrid derivative 2	DMMVPSY	N. A.	N. A.	Patented	[33]
Tacrine-dihydropyridine hybrid derivative 1	DMK0S4I	N. A.	N. A.	Patented	[33]
Tacrine-indole hybrid derivative 1	DMQ3K5B	N. A.	N. A.	Patented	[33]
Tacrine-indole hybrid derivative 2	DMH9N2T	N. A.	N. A.	Patented	[33]
Tacrine-indole hybrid derivative 3	DMUTKNW	N. A.	N. A.	Patented	[33]
Tacrine-phenothiazine hybrid derivative 1	DMNGY8R	N. A.	N. A.	Patented	[33]
Tetra-hydro-isoquinoline derivative 1	DML86IO	N. A.	N. A.	Patented	[34]
Tetra-hydro-isoquinoline derivative 2	DM5CKVF	N. A.	N. A.	Patented	[34]
Tetra-hydro-isoquinoline derivative 3	DMCZA45	N. A.	N. A.	Patented	[34]
Tetra-hydro-isoquinoline derivative 4	DMDV0MP	N. A.	N. A.	Patented	[34]
------------------------------------------------------------------------------------


⏷ Show the Full List of 54 Patented Agent(s)

20 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VELNACRINE	DMUB0EC	Cognitive impairment	6D71	Discontinued in Phase 3	[35]
Zanapezil	DMTCP8H	Alzheimer disease	8A20	Discontinued in Phase 3	[36]
Caracemide	DMNOLHT	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[37]
HP-290	DMUMGCY	Parkinson disease	8A00.0	Discontinued in Phase 2	[38], [20]
Icopezil maleate	DM5WUK9	Cognitive impairment	6D71	Discontinued in Phase 2	[39]
Physostigmine	DM2N0TO	Xerostomia	DA02.1	Discontinued in Phase 2	[40]
S-9977	DMEO6A5	Cognitive impairment	6D71	Discontinued in Phase 2	[41]
SM-10888	DMBUH7E	Cognitive impairment	6D71	Discontinued in Phase 2	[42]
TAK-802	DMHNZ31	Urinary dysfunction	GC2Z	Discontinued in Phase 2	[43]
ZIFROSILONE	DMC6H4Y	Cognitive impairment	6D71	Discontinued in Phase 2	[44], [16]
NP-61	DMXI5YW	Alzheimer disease	8A20	Discontinued in Phase 1	[45]
7-methoxytacrine	DMX5K4C	N. A.	N. A.	Terminated	[47]
ABS-301	DMCW5DJ	Alzheimer disease	8A20	Terminated	[48]
CI-1002	DMJ2P1Q	Alzheimer disease	8A20	Terminated	[49]
F-3796	DMXB8SE	Alzheimer disease	8A20	Terminated	[50]
FR-152558	DMOEYX2	Alzheimer disease	8A20	Terminated	[51]
MF-8615	DM47WS2	Alzheimer disease	8A20	Terminated	[52]
MF268	DMHV5OD	Alzheimer disease	8A20	Terminated	[53]
NP-7557	DM4B1VF	Alzheimer disease	8A20	Terminated	[54]
Ro-46-5934	DMU9JAH	Alzheimer disease	8A20	Terminated	[55]
------------------------------------------------------------------------------------


⏷ Show the Full List of 20 Discontinued Drug(s)

2 Preclinical Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PHENSERINE TARTRATE	DMIGH6W	Parkinson disease	8A00.0	Preclinical	[25], [16]
SPH-1285	DMMA2ZW	Alzheimer disease	8A20	Preclinical	[46]
------------------------------------------------------------------------------------

220 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(-)-huperzine B	DMBO9J3	Discovery agent	N.A.	Investigative	[56]
(-)-Tolserine	DMAT58Z	Discovery agent	N.A.	Investigative	[17]
(1R)-1,2,2-TRIMETHYLPROPYL (S)-METHYLPHOSPHINATE	DMCVKTB	Discovery agent	N.A.	Investigative	[53]
(2-Butyryloxy-ethyl)-trimethyl-ammonium iodide	DMLTMPC	Discovery agent	N.A.	Investigative	[57]
(2-Chloro-ethyl)-trimethyl-ammonium chloride	DM6DH15	Discovery agent	N.A.	Investigative	[57]
(2-Ethoxy-ethyl)-trimethyl-ammonium iodide	DMN7XT9	Discovery agent	N.A.	Investigative	[57]
(2-Mercapto-ethyl)-trimethyl-ammonium iodide	DMCJKOQ	Discovery agent	N.A.	Investigative	[57]
(24S)-ethylcholesta-7,9(11),22(E)-triene-3b-ol	DMPL80G	Discovery agent	N.A.	Investigative	[58]
(3-Bromo-propyl)-trimethyl-ammonium	DMUJ18K	Discovery agent	N.A.	Investigative	[57]
(3-Hydroxy-2-methyl-phenyl)-trimethyl-ammonium	DM08UQF	Discovery agent	N.A.	Investigative	[57]
(3R)-9-amino-3-methyl-1,2,3,4-tetrahydroacridine	DMEUBGY	Discovery agent	N.A.	Investigative	[59]
(4-Bromo-butyl)-trimethyl-ammonium	DMU1HFM	Discovery agent	N.A.	Investigative	[57]
(4-Iodo-butyl)-trimethyl-ammonium iodide	DMOWFE5	Discovery agent	N.A.	Investigative	[57]
(5-Bromo-pentyl)-trimethyl-ammonium	DM4EH2J	Discovery agent	N.A.	Investigative	[57]
(R)-tacrine(10)-hupyridone	DMSFA2D	Discovery agent	N.A.	Investigative	[53]
(RS)-tacrine(10)-hupyridone	DMCN6WR	Discovery agent	N.A.	Investigative	[56]
(S)-tacrine(10)-hupyridone	DMH7QZ2	Discovery agent	N.A.	Investigative	[53]
(S,S)-(-)-bis(10)-hupyridone	DMBR1JS	Discovery agent	N.A.	Investigative	[56]
(S,S)-(-)-bis(12)-hupyridone	DM6PQ8D	Discovery agent	N.A.	Investigative	[56]
1,10-bis(pyridinium)-decane dibromide	DM6VCI3	Discovery agent	N.A.	Investigative	[60]
1,11-bis(pyridinium)-undecane dibromide	DMVXYZL	Discovery agent	N.A.	Investigative	[60]
1,2-Di(berberine-9-O-yl)ethane dibromide	DM7S1D5	Discovery agent	N.A.	Investigative	[61]
1,2-NAPHTHOQUINONE	DMYXELH	Discovery agent	N.A.	Investigative	[62]
1,3-Bis-(3-imidazolidin-2-yl-phenyl)-urea	DM78UPQ	Discovery agent	N.A.	Investigative	[63]
1,3-Di(berberine-9-O-yl)ethane dibromide	DMZKUOX	Discovery agent	N.A.	Investigative	[61]
1,4-Di(berberine-9-O-yl)ethane dibromide	DM87MWN	Discovery agent	N.A.	Investigative	[61]
1,9-bis(pyridinium)-nonane dibromide	DMWC7QE	Discovery agent	N.A.	Investigative	[60]
1-(3-Bromomethyl-phenyl)-2,2,2-trifluoro-ethanone	DM58S47	Discovery agent	N.A.	Investigative	[64]
1-benzene sulfonyl-cis-2,6-dimethyl piperidine	DMQ1EVT	Discovery agent	N.A.	Investigative	[65]
1-Deoxy-1-Thio-Heptaethylene Glycol	DMAEWHB	Discovery agent	N.A.	Investigative	[53]
1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE	DMJBFN0	Discovery agent	N.A.	Investigative	[53]
10-Hydroxy-infractopicrin	DM5H73W	Discovery agent	N.A.	Investigative	[66]
2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H)-imine	DMYHFUO	Discovery agent	N.A.	Investigative	[67]
2-(Acetylamino)-2-Deoxy-a-D-Glucopyranose	DMOUG6Y	Discovery agent	N.A.	Investigative	[68]
2-(N-Morpholino)-Ethanesulfonic Acid	DMZVHSB	Discovery agent	N.A.	Investigative	[68]
2-Hex-5-enyl-5-non-8-enyl-3,4-dihydro-2H-pyrrole	DMRXW3U	Discovery agent	N.A.	Investigative	[69]
2-Hex-5-enyl-5-non-8-enyl-pyrrolidine	DM7KDQV	Discovery agent	N.A.	Investigative	[69]
2-Hex-5-enyl-5-nonyl-pyrrolidine	DMIBRYM	Discovery agent	N.A.	Investigative	[69]
2-morpholino-N-phenethylpyrimidin-4-amine	DMIQYWM	Discovery agent	N.A.	Investigative	[70]
2-Propyl-beta-carboline-2-ium iodide	DMBW6GA	Discovery agent	N.A.	Investigative	[71]
24-ethyl-cholest-7-ene-3,5,6-triol	DMQSTYZ	Discovery agent	N.A.	Investigative	[58]
24-ethylcholest-6-ene-3,5-diol	DMZIQ56	Discovery agent	N.A.	Investigative	[58]
3,4,5,6-Tetrachloro-[1,2]benzoquinone	DMSV6K5	Discovery agent	N.A.	Investigative	[72]
3,6,9,12,15-Pentaoxaheptadecane	DMY8IOP	Discovery agent	N.A.	Investigative	[53]
3,7-BIS(DIMETHYLAMINO)PHENOTHIAZIN-5-IUM	DMBIRC6	Discovery agent	N.A.	Investigative	[53]
3-(2,5-Dioxo-pyrrolidin-1-yl)-benzoic acid	DM6JTNW	Discovery agent	N.A.	Investigative	[73]
3-(2-Diethylamino-acetamino)-rutaecarpine	DM08GRF	Discovery agent	N.A.	Investigative	[74]
3-(2-Diethylamino-propionamino)-rutaecarpine	DM1FOIZ	Discovery agent	N.A.	Investigative	[74]
3-(2-N-Piperidyl-acetamino)-rutaecarpine	DM3BQO0	Discovery agent	N.A.	Investigative	[74]
3-(2-N-Piperidyl-propionamino)-rutaecarpine	DMFEHDY	Discovery agent	N.A.	Investigative	[74]
3-(2-N-Pyrrolyl-acetamino)-rutaecarpine	DMQ0A8W	Discovery agent	N.A.	Investigative	[74]
3-(2-N-Pyrrolyl-propionamino)-rutaecarpine	DM9MRTW	Discovery agent	N.A.	Investigative	[74]
3-(3-Carboxy-propionylamino)-benzoic acid	DMSJGQE	Discovery agent	N.A.	Investigative	[73]
3-(4-Benzoylpiperazine-1-carbonyl)coumarin	DMAT7VN	Discovery agent	N.A.	Investigative	[75]
3-(4-o-Tolylpiperazine-1-carbonyl)coumarin	DMIBAM2	Discovery agent	N.A.	Investigative	[75]
3-(4-Phenylpiperazin-1-carbonyl)coumarin	DMH27E0	Discovery agent	N.A.	Investigative	[75]
3-(dimethylamino)phenyl phenylcarbamate	DMM05G2	Discovery agent	N.A.	Investigative	[17]
3-hydroxy-N,N,N-trimethylbenzenaminium iodide	DMXO98C	Discovery agent	N.A.	Investigative	[76]
3-[(1s)-1-(Dimethylamino)Ethyl]Phenol	DM2KXFS	Discovery agent	N.A.	Investigative	[53]
3-[2-(1-Benzyl-piperidin-4-yl)-ethyl]-1H-indazole	DME1UNY	Discovery agent	N.A.	Investigative	[39]
3-[3-(benzylmethylamino)propoxy]xanthen-9-one	DMPVXTB	Discovery agent	N.A.	Investigative	[77]
3-[4-(benzylmethylamino)butoxy]xanthen-9-one	DMZPULH	Discovery agent	N.A.	Investigative	[77]
3-[5-(benzylmethylamino)pentyloxy]xanthen-9-one	DMQZ0A7	Discovery agent	N.A.	Investigative	[77]
3-[6-(benzylmethylamino)hexyloxy]xanthen-9-one	DM89RN3	Discovery agent	N.A.	Investigative	[77]
3-[7-(benzylmethylamino)-heptyloxy]xanthen-9-one	DMMD3G6	Discovery agent	N.A.	Investigative	[77]
3-[8-(benzylmethylamino)octyloxy]xanthen-9-one	DM31WYF	Discovery agent	N.A.	Investigative	[77]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	DMM9X0G	Discovery agent	N.A.	Investigative	[78]
4-formylphenyl-O-beta-D-ribopyranoside	DM7DW0G	Discovery agent	N.A.	Investigative	[79]
4-formylphenyl-O-beta-Dglucopyranoside	DM1VNEF	Discovery agent	N.A.	Investigative	[79]
4-ISOPROPYLPHENSERINE	DMMDGR2	Discovery agent	N.A.	Investigative	[80]
4-[4-(benzhydryloxy)piperidino]butyl benzoate	DM5Z64L	Discovery agent	N.A.	Investigative	[81]
4ALPHA-(HYDROXYMETHYL)-4ALPHA-DEMETHYLTERRITREM B	DMGYK25	Discovery agent	N.A.	Investigative	[82]
5,6-dinitroacenaphthoquinone	DM07HYA	Discovery agent	N.A.	Investigative	[62]
5-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamine	DMTJNY0	Discovery agent	N.A.	Investigative	[83]
5-Hex-5-enyl-2-nonyl-3,4-dihydro-2H-pyrrole	DMHGQRF	Discovery agent	N.A.	Investigative	[69]
6,8-Dichloro-1,2,3,4-tetrahydro-acridin-9-ylamine	DMUEFDM	Discovery agent	N.A.	Investigative	[84]
6-chlorotacrine hydrochloride	DMV0C69	Discovery agent	N.A.	Investigative	[85]
6-hydroxy-1,2,9-trimethyl-9H-beta-carbolin-2-ium	DMWLN2Y	Discovery agent	N.A.	Investigative	[86]
6-hydroxy-1,2-dimethyl-9H-beta-carbolin-2-ium	DM20DAG	Discovery agent	N.A.	Investigative	[86]
6-hydroxy-2,9-dimethyl-9H-beta-carbolin-2-ium	DMNA2M6	Discovery agent	N.A.	Investigative	[86]
6-hydroxy-2-methyl-9H-beta-carbolin-2-ium	DMAK35M	Discovery agent	N.A.	Investigative	[86]
6-methoxy-1,2-dimethyl-9H-beta-carbolin-2-ium	DMJUT70	Discovery agent	N.A.	Investigative	[86]
6-methoxy-1,9-dimethyl-9H-pyrido[3,4-b]indole	DMOHWPD	Discovery agent	N.A.	Investigative	[86]
6-methoxy-2,9-dimethyl-9H-beta-carbolin-2-ium	DMG3F7D	Discovery agent	N.A.	Investigative	[86]
6-methoxy-2-methyl-9H-beta-carbolin-2-ium	DMHITF8	Discovery agent	N.A.	Investigative	[86]
6-Methyl-4-(4-benzoylpiperazin-1-yl)coumarin	DMOVUP2	Discovery agent	N.A.	Investigative	[75]
6-Methyl-4-(4-o-tolylpiperazin-1-yl)coumarin	DMN0SYW	Discovery agent	N.A.	Investigative	[75]
6-Methyl-4-(4-phenylpiperazin-1-yl)coumarin	DMU7E3O	Discovery agent	N.A.	Investigative	[75]
7-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamine	DM1SEXA	Discovery agent	N.A.	Investigative	[83]
7-Oxo-7H-dibenzo[de,g]quinoline	DMJZR0A	Discovery agent	N.A.	Investigative	[87]
8-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamine	DMS7DA3	Discovery agent	N.A.	Investigative	[83]
9-Amino-1,2,3,4-tetrahydro-acridine-1,7-diol	DMNHZFG	Discovery agent	N.A.	Investigative	[35]
9-amino-7H-dibenzo[de,h]quinolin-7-one	DMNMVCZ	Discovery agent	N.A.	Investigative	[87]
9-Ethyl-2-methyl-beta-carboline-2-ium iodide	DM70MPJ	Discovery agent	N.A.	Investigative	[71]
9-Ethyl-beta-carboline	DMHKUO9	Discovery agent	N.A.	Investigative	[71]
9-hydrazino-1,2,3,4-tetrahydroacridine	DMOX21P	Discovery agent	N.A.	Investigative	[88]
9-O-[2-(Phenylol-1-yloxy)ethyl]berberine bromide	DMYXEJ8	Discovery agent	N.A.	Investigative	[89]
9-O-[2-(Phenylol-1-yloxy)hexyl]berberine bromide	DM081G2	Discovery agent	N.A.	Investigative	[89]
9-O-[3-(2-Pyridinoxyl)butyl]-berberine bromide	DMHRV2A	Discovery agent	N.A.	Investigative	[61]
9-O-[3-(4-Bromo-phenoxyl)butyl]-berberine bromide	DM4JG9S	Discovery agent	N.A.	Investigative	[61]
9-O-[3-(4-Nitro-phenoxyl)butyl]-berberine bromide	DMWVSPH	Discovery agent	N.A.	Investigative	[61]
9-O-[3-(Phenylamino)propyl]-berberine bromide	DMKPUWX	Discovery agent	N.A.	Investigative	[61]
9-O-[3-(Phenylol-1-yloxy)propyl]berberine bromide	DM0FNUX	Discovery agent	N.A.	Investigative	[89]
9-O-[4-(Phenylol-1-yloxy)butyl]berberine bromide	DM58XF6	Discovery agent	N.A.	Investigative	[89]
9-O-[5-(Phenylol-1-yloxy)pentyl]berberine bromide	DMPZTG9	Discovery agent	N.A.	Investigative	[89]
Allyl-trimethyl-ammonium	DM1VHCL	Discovery agent	N.A.	Investigative	[57]
AP-2238	DMQWIEL	Discovery agent	N.A.	Investigative	[90]
AP-2243	DMRYL9X	Discovery agent	N.A.	Investigative	[91]
Benzoquinone	DMNBA0G	Discovery agent	N.A.	Investigative	[72]
Beta-L-fucose	DM3BOQA	Discovery agent	N.A.	Investigative	[92]
BIS(12)-HUPERZINE B	DMWAS4Q	Discovery agent	N.A.	Investigative	[93]
Bis(14)-Huperzine B	DM58YDV	Discovery agent	N.A.	Investigative	[93]
BIS(16)-HUPERZINE B	DMYQM3B	Discovery agent	N.A.	Investigative	[93]
BIS(18)-HUPERZINE B	DM3W1T4	Discovery agent	N.A.	Investigative	[93]
BIS(20)-HUPERZINE B	DMHQKCJ	Discovery agent	N.A.	Investigative	[93]
BIS(8)-HUPERZINE B	DMER5GT	Discovery agent	N.A.	Investigative	[93]
BIS(9)-HUPERZINE B	DM5WFQM	Discovery agent	N.A.	Investigative	[93]
Bis-7-tacrine	DMVNC1R	Discovery agent	N.A.	Investigative	[70]
But-3-enyl-trimethyl-ammonium bromide	DMMHGIN	Discovery agent	N.A.	Investigative	[57]
BW284C51	DMQ3AC0	Discovery agent	N.A.	Investigative	[94], [95]
BZYX	DMA0GSY	Neurodegenerative disorder	8A20-8A23	Investigative	[4]
CAPROCTAMINE	DMDZE8N	Discovery agent	N.A.	Investigative	[96]
Carinatumins B (2)	DMUSGYQ	Discovery agent	N.A.	Investigative	[97]
CHF-2819	DMLJGVX	Discovery agent	N.A.	Investigative	[98]
CHLORANIL	DMCHGF1	Discovery agent	N.A.	Investigative	[72]
Chlorphrifos oxon	DMGBT68	Discovery agent	N.A.	Investigative	[99]
Chlorpyrifos	DMKPUI6	Discovery agent	N.A.	Investigative	[100]
CHOLINE IODIDE	DMW6U7K	Discovery agent	N.A.	Investigative	[57]
Cis-2,6-dimethyl-1-methyl sulfonyl piperidine	DMJ3HG9	Discovery agent	N.A.	Investigative	[65]
CLEBOPRIDE	DMTLOU6	Discovery agent	N.A.	Investigative	[63]
CORONARIDINE	DMZBUE7	Discovery agent	N.A.	Investigative	[101]
CP-126998	DM3ZIDT	Discovery agent	N.A.	Investigative	[102]
CRYPTADINE B	DM92IK8	Discovery agent	N.A.	Investigative	[103]
DECIDIUM	DM4SWYX	Discovery agent	N.A.	Investigative	[56]
Dimethyl-pent-4-enyl-ammonium bromide	DMO0UI8	Discovery agent	N.A.	Investigative	[57]
Ethyl octylfluorophosphonate	DMXMRK7	Discovery agent	N.A.	Investigative	[99]
ETHYLPHENSERINE	DMT51QD	Discovery agent	N.A.	Investigative	[20]
Fucose	DMAHMSV	N. A.	N. A.	Investigative	[68]
Galanthamine derivative	DMAFE24	Discovery agent	N.A.	Investigative	[56]
GANSTIGMINE	DMFT4GU	Discovery agent	N.A.	Investigative	[56]
GENESERINE	DMAUFLQ	Discovery agent	N.A.	Investigative	[98]
HALOXYSTEROL A	DM4AEGQ	Discovery agent	N.A.	Investigative	[58]
HALOXYSTEROL B	DMD8O7S	Discovery agent	N.A.	Investigative	[58]
Haloxysterol C	DMU1DHM	Discovery agent	N.A.	Investigative	[58]
Haloxysterol D	DMWCZLT	Discovery agent	N.A.	Investigative	[58]
Hexyl-trimethyl-ammonium	DM9EW7V	Discovery agent	N.A.	Investigative	[57]
Huprine X	DMTPXB6	Discovery agent	N.A.	Investigative	[56]
Huprine Y	DMYH0XQ	N. A.	N. A.	Investigative	[104]
Huprine-Tacrine Heterodimer	DMJ4ME7	Discovery agent	N.A.	Investigative	[105]
Infractopicrin	DMV6UJ5	Discovery agent	N.A.	Investigative	[66]
Iso-OMPA	DMFX16H	Discovery agent	N.A.	Investigative	[95]
Isopropyl dodecylfluorophosphonate	DML54EA	Discovery agent	N.A.	Investigative	[99]
Isosorbide-2-(methylcarbamate)-5-benzoate	DMC7MLN	Discovery agent	N.A.	Investigative	[95]
Isosorbide-2-(methylcarbamate)-5-mononitrate	DMEKMOF	Discovery agent	N.A.	Investigative	[95]
Isosorbide-2-benzylcarbamate-5-cyclopentanoate	DMWDQ90	Discovery agent	N.A.	Investigative	[95]
Isosorbide-2-benzylcarbamate-5-cyclopropanoate	DM8E2L6	Discovery agent	N.A.	Investigative	[95]
Isosorbide-2-benzylcarbamate-5-tosylate	DMCHSWQ	Discovery agent	N.A.	Investigative	[95]
Isosorbide-di-(4-nitrophenyl carbamate)	DMPA2ON	Discovery agent	N.A.	Investigative	[106]
Isosorbide-di-(benzylcarbamate)	DMFVN71	Discovery agent	N.A.	Investigative	[106]
Isosorbide-di-(ethylcarbamate)	DMTHWXO	Discovery agent	N.A.	Investigative	[106]
Isosorbide-di-phenylcarbamate	DMT1ZGM	Discovery agent	N.A.	Investigative	[106]
LAWSARITOL	DM5GNFO	Discovery agent	N.A.	Investigative	[58]
LIPOCRINE	DMUIVCX	Discovery agent	N.A.	Investigative	[107]
LYSICAMINE	DMIZQW6	Discovery agent	N.A.	Investigative	[108]
MEMOQUIN	DM9S30P	Discovery agent	N.A.	Investigative	[107]
MESUAGENIN A	DMZ12GE	Discovery agent	N.A.	Investigative	[109]
MESUAGENIN B	DMKXG3V	Discovery agent	N.A.	Investigative	[109]
Mesuagenin D	DMLZGO7	Discovery agent	N.A.	Investigative	[109]
Methyl Phosphinic Acid	DM096SI	Discovery agent	N.A.	Investigative	[68]
MMB-4	DMUL4PE	Poison intoxication	NE6Z	Investigative	[4]
Monoisopropylphosphorylserine	DM0OFT6	Discovery agent	N.A.	Investigative	[68]
N,N'-(1',10'-decylene)-bis-(-)-nor-MEP	DMIX0CT	Discovery agent	N.A.	Investigative	[110]
N,N'-(1',11'-undecydene)-bis-(-)-nor-MEP	DM5NVIO	Discovery agent	N.A.	Investigative	[110]
N,N'-(1',12'-dodecydene)-bis-(-)-nor-MEP	DMWI06H	Discovery agent	N.A.	Investigative	[110]
N,N'-(1',5'-pentylene)-bis-(-)-nor-MEP	DMBPC0K	Discovery agent	N.A.	Investigative	[110]
N,N'-(1',6-hexylene)-bis-(-)-nor-MEP	DMU4BIW	Discovery agent	N.A.	Investigative	[110]
N,N'-(1',7'-heptylene)-bis-(-)-nor-MEP	DMSORHA	Discovery agent	N.A.	Investigative	[110]
N,N'-(1',8'-octylene)-bis-(-)-nor-MEP	DMHFYK2	Discovery agent	N.A.	Investigative	[110]
N,N'-(1',9'-nonylene)-bis-(-)-nor-MEP	DMIWF7U	Discovery agent	N.A.	Investigative	[110]
N-(14-methylallyl)norgalanthamine	DMW460V	Discovery agent	N.A.	Investigative	[111]
N-ALLYLNORGALANTHAMINE	DMRXA8N	Discovery agent	N.A.	Investigative	[111]
N-allylnorlitebamine	DM5W2VK	Discovery agent	N.A.	Investigative	[112]
N-benzyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine	DM0ZXBQ	Discovery agent	N.A.	Investigative	[70]
N-benzyl-2-morpholinopyrimidin-4-amine	DMQCGFL	Discovery agent	N.A.	Investigative	[70]
N-benzyl-2-thiomorpholinopyrimidin-4-amine	DMRJMGK	Discovery agent	N.A.	Investigative	[70]
N-benzylnorlitebamine	DMVEZH1	Discovery agent	N.A.	Investigative	[112]
N-butylnorlitebamine	DMNFTO6	Discovery agent	N.A.	Investigative	[112]
N-isobutylnorlitebamine	DM9Z6VP	Discovery agent	N.A.	Investigative	[112]
N-isopropylnorlitebamine	DMG8NB0	Discovery agent	N.A.	Investigative	[112]
N-isopropylnorlitebamineN-methoiodide	DMDVO9T	Discovery agent	N.A.	Investigative	[112]
N-Methyl-1'H-phenothiazine-1'-carboxamide	DMK8VZM	Discovery agent	N.A.	Investigative	[113]
N-n-dodecyl-7-methoxytacrine hydrochloride	DM8FOSR	Discovery agent	N.A.	Investigative	[47]
N-n-heptyl-7-methoxytacrine hydrochloride	DMA8R47	Discovery agent	N.A.	Investigative	[47]
N-n-hexyl-7-methoxytacrine hydrochloride	DM4ZMG6	Discovery agent	N.A.	Investigative	[47]
N-n-nonyl-7-methoxytacrine hydrochloride	DMLH23M	Discovery agent	N.A.	Investigative	[47]
N-n-octyl-7-methoxytacrine hydrochloride	DMLC257	Discovery agent	N.A.	Investigative	[47]
N-n-pentyl-7-methoxytacrine hydrochloride	DMWAK5V	Discovery agent	N.A.	Investigative	[47]
N-n-propyl-7-methoxytacrine hydrochloride	DMCN78A	Discovery agent	N.A.	Investigative	[47]
N-phenethyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine	DMJQZMH	Discovery agent	N.A.	Investigative	[70]
N-propylnorlitebamine	DM3JQYD	Discovery agent	N.A.	Investigative	[112]
NPRx-30	DMYB2EZ	Neurodegenerative disorder	8A20-8A23	Investigative	[4]
NSC-23180	DMJ91Y7	Discovery agent	N.A.	Investigative	[62]
OBIDOXIME	DMM98BC	Discovery agent	N.A.	Investigative	[100]
Paraoxon	DMN4ZKC	Discovery agent	N.A.	Investigative	[99]
Petrosamine	DMYIEOJ	Discovery agent	N.A.	Investigative	[114]
Propidium	DMZ1FRS	Discovery agent	N.A.	Investigative	[68]
Pseudocolumbamine trifluoroacetate	DM0E5G9	Discovery agent	N.A.	Investigative	[108]
Pseudopalmatine trifluoroacetate	DM4HE1V	Discovery agent	N.A.	Investigative	[108]
TACRINE(8)-4-AMINOQUINOLINE	DMOWHER	Discovery agent	N.A.	Investigative	[53]
TASPINE	DM9S5DV	Discovery agent	N.A.	Investigative	[115]
TERRITREM B	DMPX7QS	Discovery agent	N.A.	Investigative	[116]
Tetraethylene Glycol	DMH4AGL	Discovery agent	N.A.	Investigative	[68]
THIOCTIC ACID	DMNFCXW	Discovery agent	N.A.	Investigative	[117]
TOLSERINE	DMPTM6V	Discovery agent	N.A.	Investigative	[20]
TRIMEDOXIME	DMPXHTY	Discovery agent	N.A.	Investigative	[100]
Trimethyl-(3-nitro-phenyl)-ammonium iodide	DMQXPMB	Discovery agent	N.A.	Investigative	[57]
Trimethyl-(4-oxo-pentyl)-ammonium iodide	DMJ4I98	Discovery agent	N.A.	Investigative	[57]
TURBINATINE	DMLDYVB	Discovery agent	N.A.	Investigative	[118]
Voacangine	DMA106W	Discovery agent	N.A.	Investigative	[101]
XANTHOSTIGMINE	DM38TLN	Discovery agent	N.A.	Investigative	[119]
------------------------------------------------------------------------------------


⏷ Show the Full List of 220 Investigative Drug(s)

References

1	Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66.
2	The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5.
3	Neuromuscular blocking agents and axial teratogenesis in the avian embryo. Can axial morphogenetic disorders by explained by pharmacological action upon muscle tissue Teratology. 1981 Apr;23(2):259-71.
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6	Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
7	Neuromuscular blockade, reversal agent use, and operating room time: retrospective analysis of US inpatient surgeries. Curr Med Res Opin. 2009 Apr;25(4):943-50.
8	Stabilization of Torpedo californica acetylcholinesterase by reversible inhibitors. Biochemistry. 2009 Jan 27;48(3):563-74.
9	[From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33.
10	Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease. Neuroreport. 2009 Feb 18;20(3):285-8.
11	Acetylcholinesterase inhibitors enhance cognitive functions in rats following hypobaric hypoxia. Behav Brain Res. 2009 Oct 12;203(1):1-14.
12	Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res. 2002 Sep 13;949(1-2):162-70.
13	Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502.
14	Acetylcholinesterase activity in Corbicula fluminea Mull., as a biomarker of organophosphate pesticide pollution in Pinacanauan River, Philippines. Environ Monit Assess. 2010 Jun;165(1-4):331-40.
15	Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl. 2002 Jun;(127):6-19.
16	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
17	Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93.
18	Activity, mechanism of action and pharmacokinetics of 2-tert-butylbenzothiazole and CGP 6140 (amocarzine) antifilarial drugs. Acta Trop. 1992 Aug;51(3-4):195-211.
19	Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies. CNS Drug Rev. 2001 Winter;7(4):369-86.
20	Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based vi... J Med Chem. 2010 Sep 9;53(17):6490-505.
21	The memory ameliorating effects of INM-176, an ethanolic extract of Angelica gigas, against scopolamine- or Abeta(1-42)-induced cognitive dysfunction in mice. J Ethnopharmacol. 2012 Sep 28;143(2):611-20.
22	Potential clinical use of an adrenergic/cholinergic agent (HP 128) in the treatment of Alzheimer's disease. Ann N Y Acad Sci. 1991;640:263-7.
23	Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.
24	A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease. Br J Clin Pharmacol. 2013 May;75(5):1231-9.
25	An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res. 2005 Jul;2(3):281-90.
26	Effects of T-82, a novel acetylcholinesterase inhibitor, on impaired learning and memory in passive avoidance task in rats. Eur J Pharmacol. 2003 Mar 28;465(1-2):97-103.
27	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
28	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
29	Phase I clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: tolerance and pharmacokinetics study of escalating single oral doses. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):141-7.
30	Oral administration of KW-5092, a novel gastroprokinetic agent with acetylcholinesterase inhibitory and acetylcholine release enhancing activities, causes a dose-dependent increase in the blood acetylcholine content of beagle dogs. Neurosci Lett. 1997 Mar 28;225(1):25-8.
31	Preclinical and first-in-human evaluation of PRX-105, a PEGylated, plant-derived, recombinant human acetylcholinesterase-R. Toxicol Appl Pharmacol. 2015 Sep 15;287(3):202-9.
32	A sensitive method for the determination of the novel cholinesterase inhibitor ZT-1 and its active metabolite huperzine A in rat blood using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2004;18(6):651-6.
33	Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476.
34	A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465.
35	Synthesis and biological activity of putative mono-hydroxylated metabolites of velnacrine, Bioorg. Med. Chem. Lett. 2(8):865-870 (1992).
36	Effect of oral administration of zanapezil (TAK-147) for 21 days on acetylcholine and monoamines levels in the ventral hippocampus of freely moving rats. Br J Pharmacol. 2005 Aug;145(8):1035-44.
37	Biochemical pharmacology of N-acetyl-N-(methylcarbamoyloxy)-N'-methylurea (caracemide; NSC-253272). Biochem Pharmacol. 1986 Aug 15;35(16):2781-7.
38	NXX-066 in patients with Alzheimer's disease: a bridging study. Life Sci. 1999;64(14):1215-21.
39	A docking score function for estimating ligand-protein interactions: application to acetylcholinesterase inhibition. J Med Chem. 2004 Oct 21;47(22):5492-500.
40	The effects of physostigmine on acetylcholinesterase activity of CSF plasma and brain. A comparison of intravenous and intraventricular administration in beagle dogs. Neuropharmacology. 1986 Oct;25(10):1167-77.
41	Xanthine derivatives IBMX and S-9977-2 potentiate transmission at an Aplysia central cholinergic synapse. Brain Res. 1992 Jul 17;586(1):78-85.
42	Pharmacological and biochemical assessment of SM-10888, a novel cholinesterase inhibitor. Jpn J Pharmacol. 1990 Jun;53(2):145-55.
43	Effects of TAK-802, a novel acetylcholinesterase inhibitor, on distension-induced rhythmic bladder contractions in rats and guinea pigs. Eur J Pharmacol. 2004 Feb 6;485(1-3):299-305.
44	Acetylcholinesterase inhibition by zifrosilone: pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1995 Jul;58(1):54-61.
45	Potent beta-amyloid modulators. Neurodegener Dis. 2008;5(3-4):153-6.
46	Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol Psychiatry. 2001 Feb 1;49(3):289-99.
47	Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5.
48	Novel tacrine analogues for potential use against Alzheimer's disease: potent and selective acetylcholinesterase inhibitors and 5-HT uptake inhibitors. J Med Chem. 1997 Oct 24;40(22):3516-23.
49	PD 142676 (CI 1002), a novel anticholinesterase and muscarinic antagonist. Mol Neurobiol. 1994 Aug-Dec;9(1-3):93-106.
50	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004498)
51	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006757)
52	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006922)
53	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
54	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017551)
55	A novel acetylcholinesterase inhibitor, Ro 46-5934, which interacts with muscarinic M2 receptors. Biochem Soc Trans. 1994 Aug;22(3):755-8.
56	Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely... J Med Chem. 2008 Jun 12;51(11):3154-70.
57	Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71.
58	Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80.
59	Synthesis and AChE inhibitory activity of new chiral tetrahydroacridine analogues from terpenic cyclanones. Eur J Med Chem. 2010 Feb;45(2):526-35.
60	Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for My... Bioorg Med Chem Lett. 2010 Mar 1;20(5):1763-6.
61	Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84.
62	Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34.
63	Efficient method for high-throughput virtual screening based on flexible docking: discovery of novel acetylcholinesterase inhibitors. J Med Chem. 2004 Sep 23;47(20):4818-28.
64	A structure-based design approach to the development of novel, reversible AChE inhibitors. J Med Chem. 2001 Sep 27;44(20):3203-15.
65	Active site directed docking studies: synthesis and pharmacological evaluation of cis-2,6-dimethyl piperidine sulfonamides as inhibitors of acetylc... Eur J Med Chem. 2009 Oct;44(10):4057-62.
66	Acetylcholinesterase inhibitors from the toadstool Cortinarius infractus. Bioorg Med Chem. 2010 Mar 15;18(6):2173-2177.
67	Homobivalent quinazolinimines as novel nanomolar inhibitors of cholinesterases with dirigible selectivity toward butyrylcholinesterase. J Med Chem. 2006 Sep 7;49(18):5411-3.
68	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
69	Acetylcholinesterase inhibition by alkaloids of the ant's venom Monomorium minutum, Bioorg. Med. Chem. Lett. 5(11):1131-1132 (1995).
70	Design, synthesis and evaluation of 2,4-disubstituted pyrimidines as cholinesterase inhibitors. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3606-9.
71	Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7.
72	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15.
73	Synthesis, anticholinesterase activity and structure-activity relationships of m-Aminobenzoic acid derivatives. Bioorg Med Chem Lett. 2003 May 19;13(10):1825-7.
74	Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem. 2010 Apr;45(4):1415-23.
75	Design, synthesis, and acetylcholinesterase inhibitory activity of novel coumarin analogues. Bioorg Med Chem. 2008 Sep 1;16(17):8011-21.
76	Homo- and hetero-bivalent edrophonium-like ammonium salts as highly potent, dual binding site AChE inhibitors. Bioorg Med Chem. 2008 Aug 1;16(15):7450-6.
77	Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85.
78	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
79	Synthesis and biological evaluation of helicid analogues as novel acetylcholinesterase inhibitors. Eur J Med Chem. 2008 Jan;43(1):166-73.
80	Design, synthesis, evaluation and QSAR analysis of N(1)-substituted norcymserine derivatives as selective butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1718-20.
81	Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abe... Bioorg Med Chem. 2007 Oct 15;15(20):6596-607.
82	Structure and anti-acetylcholinesterase activity of 4 alpha-(hydroxymethyl)-4 alpha-demethylterritrem B. J Nat Prod. 1997 Aug;60(8):842-3.
83	The synthesis and in vitro acetylcholinesterase and butyrylcholinesterase inhibitory activity of tacrine (Cognex ) derivaties, Bioorg. Med. Chem. Lett. 2(8):861-864 (1992).
84	Novel and potent tacrine-related hetero- and homobivalent ligands for acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem Lett. 2001 Jul 9;11(13):1779-82.
85	Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds. J Med Chem. 2009 Sep 10;52(17):5365-79.
86	6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3.
87	Synthesis, biological evaluation and molecular modeling of oxoisoaporphine and oxoaporphine derivatives as new dual inhibitors of acetylcholinester... Eur J Med Chem. 2009 Jun;44(6):2523-32.
88	Novel heterobivalent tacrine derivatives as cholinesterase inhibitors with notable selectivity toward butyrylcholinesterase. J Med Chem. 2006 Dec 14;49(25):7540-4.
89	Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1244-51.
90	Targeting Alzheimer's disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238. Bioorg Med Chem. 2010 Mar 1;18(5):1749-60.
91	Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorg Med Chem Lett. 2008 Jan 1;18(1):423-6.
92	DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
93	Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors. J Med Chem. 2005 Feb 10;48(3):655-7.
94	Cholinesterases: new roles in brain function and in Alzheimer's disease. Neurochem Res. 2003 Apr;28(3-4):515-22.
95	Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9.
96	Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inne... J Med Chem. 2008 Nov 27;51(22):7308-12.
97	Carinatumins A-C, new alkaloids from Lycopodium carinatum inhibiting acetylcholinesterase. Bioorg Med Chem. 2007 Feb 15;15(4):1703-7.
98	Structural determinants of Torpedo californica acetylcholinesterase inhibition by the novel and orally active carbamate based anti-alzheimer drug g... J Med Chem. 2006 Aug 24;49(17):5051-8.
99	Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol. 2008 Jun;4(6):373-8.
100	Synthesis of the novel series of bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against chlorpy... Bioorg Med Chem Lett. 2006 Feb;16(3):622-7.
101	Indole alkaloids from Ervatamia hainanensis with potent acetylcholinesterase inhibition activities. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6185-7.
102	PET imaging of brain acetylcholinesterase using [11C]CP-126,998, a brain selective enzyme inhibitor. Synapse. 2002 Jul;45(1):1-9.
103	Cryptadines A and B, novel C27N3-type pentacyclic alkaloids from Lycopodium cryptomerinum. Bioorg Med Chem. 2007 Dec 15;15(24):7803-8.
104	Synthesis and structure-activity relationship of Huprine derivatives as human acetylcholinesterase inhibitors. Bioorg Med Chem. 2009 Jul 1;17(13):4523-36.
105	Synthesis and pharmacological evaluation of huprine-tacrine heterodimers: subnanomolar dual binding site acetylcholinesterase inhibitors. J Med Chem. 2005 Mar 24;48(6):1701-4.
106	Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability. Bioorg Med Chem. 2010 Feb;18(3):1045-53.
107	Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks. J Med Chem. 2009 Dec 10;52(23):7883-6.
108	Characterization of Acetylcholinesterase Inhibitory Constituents from Annona glabra Assisted by HPLC Microfractionation. J Nat Prod. 2010 Oct 22;73(10):1632-5.
109	4-Phenylcoumarins from Mesua elegans with acetylcholinesterase inhibitory activity. Bioorg Med Chem. 2010 Nov 15;18(22):7873-7.
110	Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36.
111	N-Alkylated galanthamine derivatives: Potent acetylcholinesterase inhibitors from Leucojum aestivum. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2263-6.
112	Litebamine N-homologues: preparation and anti-acetylcholinesterase activity. J Nat Prod. 1998 Jan;61(1):46-50.
113	Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244.
114	Petrosamine, a potent anticholinesterase pyridoacridine alkaloid from a Thai marine sponge Petrosia n. sp. Bioorg Med Chem. 2008 Jul 1;16(13):6560-7.
115	Taspine: bioactivity-guided isolation and molecular ligand-target insight of a potent acetylcholinesterase inhibitor from Magnolia x soulangiana. J Nat Prod. 2006 Sep;69(9):1341-6.
116	Acetylcholinesterase inhibition by territrem B derivatives. J Nat Prod. 1995 Jun;58(6):857-62.
117	Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem. 2008 Feb 14;51(3):347-72.
118	Indole glucoalkaloids from Chimarrhis turbinata and their evaluation as antioxidant agents and acetylcholinesterase inhibitors. J Nat Prod. 2004 Nov;67(11):1882-5.
119	Acetylcholinesterase inhibitors: synthesis and structure-activity relationships of omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)- methyl]aminoalkox... J Med Chem. 1998 Oct 8;41(21):3976-86.
120	How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
121	Kinetic characterization of cholinesterases and a therapeutically valuable cocaine hydrolase for their catalytic activities against heroin and its metabolite 6-monoacetylmorphine. Chem Biol Interact. 2018 Sep 25;293:107-114.